Literature DB >> 16356580

Evaluation of a bioartificial liver based on a nonwoven fabric bioreactor with porcine hepatocytes in pigs.

Lan Juan Li1, Wei Bo Du, Yi Min Zhang, Jun Li, Xiao Ping Pan, Jia Jia Chen, Hong Cui Cao, Yu Chen, Yue Mei Chen.   

Abstract

BACKGROUND/AIMS: We developed a bioartificial liver (BAL) based on a direct hemoperfusion typed nonwoven fabric bioreactor containing porcine hepatocytes. In this study, the efficacy of our BAL was evaluated with a pig fulminant hepatic failure (FHF) model.
METHODS: FHF was induced with intravenous administration of D-galactosamine (1.3 g/kg) in each pig. Twelve hours post D-galactosamine injection, fifteen pigs were divided into: a BAL group (n = 5), in which pigs received the BAL treatment with 1.0 to 1.3 x 10(9) hepatocytes for 6 h, a sham BAL group (n = 5), in which pigs received the BAL treatment without hepatocytes, and a FHF group (n = 5), in which pigs only received intensive care. Parameters related to liver function and animal survival up to 168 h were determined.
RESULTS: In the BAL group, blood ammonia and plasma lactate levels were lower, and serum glucose levels and Fischer index were higher than those in the other two groups. Survival time of pigs in the BAL group was significantly prolonged as compared with the sham BAL and the FHF group.
CONCLUSIONS: The BAL based on a nonwoven fabric bioreactor containing porcine hepatocytes appears to be effective in the treatment of FHF in pigs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16356580     DOI: 10.1016/j.jhep.2005.08.006

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  7 in total

1.  Comparison between bioartificial and artificial liver for the treatment of acute liver failure in pigs.

Authors:  Yasushi Kawazoe; Susumu Eguchi; Nozomu Sugiyama; Yukio Kamohara; Hikaru Fujioka; Takashi Kanematsu
Journal:  World J Gastroenterol       Date:  2006-12-14       Impact factor: 5.742

Review 2.  An overview of animal models for investigating the pathogenesis and therapeutic strategies in acute hepatic failure.

Authors:  María-Jesús Tuñón; Marcelino Alvarez; Jesús-M Culebras; Javier González-Gallego
Journal:  World J Gastroenterol       Date:  2009-07-07       Impact factor: 5.742

3.  Integration of single-layer skin hollow fibers and scaffolds develops a three-dimensional hybrid bioreactor for bioartificial livers.

Authors:  Shichang Zhang; Li Chen; Tao Liu; Zhengguo Wang; Yingjie Wang
Journal:  J Mater Sci Mater Med       Date:  2013-08-21       Impact factor: 3.896

4.  Therapeutic potential of transplanted placental mesenchymal stem cells in treating Chinese miniature pigs with acute liver failure.

Authors:  Hongcui Cao; Jinfeng Yang; Jiong Yu; Qiaoling Pan; Jianzhou Li; Pengcheng Zhou; Yanyuan Li; Xiaoping Pan; Jun Li; Yingjie Wang; Lanjuan Li
Journal:  BMC Med       Date:  2012-06-06       Impact factor: 8.775

5.  Novel D-galactosamine-induced cynomolgus monkey model of acute liver failure.

Authors:  Lei Feng; Lei Cai; Guo-Lin He; Jun Weng; Yang Li; Ming-Xin Pan; Ze-Sheng Jiang; Qing Peng; Yi Gao
Journal:  World J Gastroenterol       Date:  2017-11-14       Impact factor: 5.742

6.  Therapeutic potential of menstrual blood stem cells in treating acute liver failure.

Authors:  Pan-Pan Cen; Lin-Xiao Fan; Jie Wang; Jia-Jia Chen; Lan-Juan Li
Journal:  World J Gastroenterol       Date:  2019-11-07       Impact factor: 5.742

7.  Efficacy of Fluidized Bed Bioartificial Liver in Treating Fulminant Hepatic Failure in Pigs: A Metabolomics Study.

Authors:  Pengcheng Zhou; Li Shao; Lifu Zhao; Guoliang Lv; Xiaoping Pan; Anye Zhang; Jianzhou Li; Ning Zhou; Deying Chen; Lanjuan Li
Journal:  Sci Rep       Date:  2016-05-19       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.